Regentis Biomaterials Announces First Patient Treated in its Cartilage Clinical Study 

Regentis Biomaterials announced today that the first patient has been successfully operated in its’
Cartilage Clinical Study. The study  a single arm, open label, multi-center study to evaluate the safety
and performance of articular cartilage lesions located on the femoral condyle, with the company’s
proprietary tissue repair matrix, GerlinC. The procedure was performed by Sven Anders, MD, at
Regensburg University Hospital, Regensburg, Germany.

GelrinC is a biodegradable, of-the-shelf, a-cellular implant made of polyethylene glycol diacrylate
(PEG-DA) covalently conjugated with a structural backbone of denatured fibrinogen chains. The
device comes in a liquid form, injected into the lesion site and polymerized in situ into a stable
hydrogel solid matrix. The device gradually degrades over a period of 6-12 months whilst enabling
natural functional tissue to fill the space occupied previously by the implant.

The first patient was had a single lesion on his femoral condyle. The lesion was successfully treated
with GelrinC. The patient was discharged from the hospital and is doing well.

“We are pleased Dr. Anders has successfully implanted GelrinC in the patient lesion, this is a key
milestone for the company in its path to prove safety and efficacy of GelrinC as a treatment for
cartilage repair” said Yehiel Tal, the company’s CEO, “We believe that Regentis technology platform
GelrinC offers a significant therapeutic advantage to patients with local cartilage lesions”

About Regentis Biomaterials:

Established in 2004, Regentis Biomaterials is a tissue repair company that is developing and
commercializing innovative biodegradable hydrogels for the local repair of damaged cartilage and
bone.  Our platform technology is a family of hydrogels called Gelrin™. These gels can be injected or
applied to a specific local site and offer beneficial properties for the local repair of damaged tissue
such as cartilage and bone.

The Gelrin™ technology offers off-the-shelf products that are designed to be suitable for both open
surgery and minimally invasive procedures. An ideal solution for physicians and their patients, the
products are easy to implant and have been shown to stimulate the regeneration of healthy cartilage
and bone tissue. Regentis’ first orthopedic product is GelrinC, a biodegradable hydrogel for articular
cartilage regeneration. Additional pipeline products include GelrinB – a biodegradable hydrogel for
bone regeneration; and GelrinA – a void filling matrix for aesthetic indications.

CAUTION: GelrinC is an investigational product, not available in Europe and in the US